HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $48

Benzinga Newsdesk www.benzinga.com Neutral 59.1%

Neg 0% Neu 59.1% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield maintains LENZ Therapeutics (NASDAQ:LENZ) with a Buy and lowers the price target from $56 to $48.